



ELSEVIER

Contents lists available at [ScienceDirect](#)

Critical Reviews in Oncology / Hematology

journal homepage: www.elsevier.com/locate/critrevonc



Corrigendum to “Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario” [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150–156]



Alfredo Addeo^{a,*}, Fabrizio Tabbò^b, Tim Robinson^c, Lucio Buffoni^b, Silvia Novello^b

^a Oncology Department, University Hospital Geneva, Rue Gabrielle-Perret-Gentil 4, Geneva, CH, Switzerland

^b Oncology Department, San Luigi Hospital University of Turin, Orbassano, Turin, Italy

^c Oncology Department, Bristol University Hospital Trust, Horfield Road, Bristol, UK

The authors regret that there was a typographical error in text when the paper was published. The article mentions a 1603 EORTC trial but

this should have read as 1613 EORTC trial.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.critrevonc.2017.12.015>

* Corresponding author.

<https://doi.org/10.1016/j.critrevonc.2018.06.018>